Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Bemcentinib (Primary) ; Bevacizumab (Primary) ; Pembrolizumab (Primary) ; Rucaparib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms MiST
- 01 Oct 2018 Status changed from not yet recruiting to recruiting.
- 26 Sep 2018 According to the trial design presented at the 19th World Conference on Lung Cancer, first patient first visit is anticipated in Q3 2018.
- 26 Sep 2018 Trial design of MIST3 presented at the 19th World Conference on Lung Cancer.